Ignite Creation Date:
2025-12-24 @ 2:09 PM
Ignite Modification Date:
2025-12-29 @ 4:37 PM
Study NCT ID:
NCT05907395
Status:
COMPLETED
Last Update Posted:
2025-04-10
First Post:
2023-06-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Any untoward findings identified on physical and/or neurological examinations, cardiac monitoring conducted during the active collection period were captured as adverse events, if those findings met the definition of an AE.'}}, 'adverseEventsModule': {'timeFrame': 'Day 1 of first dose up to maximum of 35 days post last dose (up to 60 days)', 'eventGroups': [{'id': 'EG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 3, 'seriousNumAtRisk': 5, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 3, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 3, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 5, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.', 'otherNumAtRisk': 12, 'deathsNumAtRisk': 12, 'otherNumAffected': 8, 'seriousNumAtRisk': 12, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 3, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG013', 'title': 'Placebo: CRYS/Fasted Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fasted condition.', 'otherNumAtRisk': 2, 'deathsNumAtRisk': 2, 'otherNumAffected': 2, 'seriousNumAtRisk': 2, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG014', 'title': 'Placebo: CRYS/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fed condition.', 'otherNumAtRisk': 2, 'deathsNumAtRisk': 2, 'otherNumAffected': 1, 'seriousNumAtRisk': 2, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG015', 'title': 'Placebo: SDD/Fasted Combined for All Cohorts', 'description': 'Participants received placebo matched to PF-07293893 SDD in fasted condition.', 'otherNumAtRisk': 18, 'deathsNumAtRisk': 18, 'otherNumAffected': 6, 'seriousNumAtRisk': 18, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG016', 'title': 'Placebo: SDD/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 SDD in fed condition.', 'otherNumAtRisk': 2, 'deathsNumAtRisk': 2, 'otherNumAffected': 1, 'seriousNumAtRisk': 2, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Palpitations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Sinus tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Aphthous ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Gastrointestinal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Application site irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Chest discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Feeling cold', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Influenza like illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Vessel puncture site haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Liver function test increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dizziness postural', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Head discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 6}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 4}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 2}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pollakiuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Hyperventilation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Throat irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Acne', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Rash pruritic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Seborrhoeic dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 18, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 2, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}, {'value': '2', 'groupId': 'OG013'}, {'value': '2', 'groupId': 'OG014'}, {'value': '18', 'groupId': 'OG015'}, {'value': '2', 'groupId': 'OG016'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}, {'id': 'OG013', 'title': 'Placebo: CRYS/Fasted Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fasted condition.'}, {'id': 'OG014', 'title': 'Placebo: CRYS/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fed condition.'}, {'id': 'OG015', 'title': 'Placebo: SDD/Fasted Combined for All Cohorts', 'description': 'Participants received placebo matched to PF-07293893 SDD in fasted condition.'}, {'id': 'OG016', 'title': 'Placebo: SDD/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 SDD in fed condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '8', 'groupId': 'OG008'}, {'value': '2', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '3', 'groupId': 'OG011'}, {'value': '4', 'groupId': 'OG012'}, {'value': '2', 'groupId': 'OG013'}, {'value': '1', 'groupId': 'OG014'}, {'value': '6', 'groupId': 'OG015'}, {'value': '1', 'groupId': 'OG016'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 of first dose up to maximum of 35 days post last dose (up to 60 days)', 'description': 'An Adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events with onset dates on or after the start of the study drug.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}, {'value': '2', 'groupId': 'OG013'}, {'value': '2', 'groupId': 'OG014'}, {'value': '18', 'groupId': 'OG015'}, {'value': '2', 'groupId': 'OG016'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}, {'id': 'OG013', 'title': 'Placebo: CRYS/Fasted Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fasted condition.'}, {'id': 'OG014', 'title': 'Placebo: CRYS/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fed condition.'}, {'id': 'OG015', 'title': 'Placebo: SDD/Fasted Combined for All Cohorts', 'description': 'Participants received placebo matched to PF-07293893 SDD in fasted condition.'}, {'id': 'OG016', 'title': 'Placebo: SDD/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 SDD in fed condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}, {'value': '3', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '3', 'groupId': 'OG011'}, {'value': '3', 'groupId': 'OG012'}, {'value': '2', 'groupId': 'OG013'}, {'value': '1', 'groupId': 'OG014'}, {'value': '7', 'groupId': 'OG015'}, {'value': '1', 'groupId': 'OG016'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 of first dose up to maximum of 9 days post last dose (up to 34 days)', 'description': 'Following parameters were analyzed for laboratory abnormalities: hematology (lymphocytes \\<0.8\\*lower limit of normal \\[LLN\\], lymphocytes/leukocytes \\<0.8\\*LLN, neutrophils \\<0.8\\*LLN, neutrophils/leukocytes \\<0.8\\*LLN, eosinophils/leukocytes \\>1.2\\*upper limit of normal \\[ULN\\], monocytes \\>1.2\\*ULN, monocytes/leukocytes \\>1.2\\*ULN); clinical chemistry (aspartate aminotransferase \\>3.0\\*ULN, potassium \\>1.1\\*ULN, creatine kinase \\>2.0\\*ULN); urinalysis (urine specific gravity \\<1.003 ,\\>1.030, ketones \\>=1, urine hemoglobin \\>=1, urobilinogen \\>=1, urine bilirubin \\>=1, leukocyte esterase \\>=1). In this outcome measure, participants with any laboratory abnormalities are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Clinically Significant Changes in Vital Signs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}, {'value': '2', 'groupId': 'OG013'}, {'value': '2', 'groupId': 'OG014'}, {'value': '18', 'groupId': 'OG015'}, {'value': '2', 'groupId': 'OG016'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}, {'id': 'OG013', 'title': 'Placebo: CRYS/Fasted Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fasted condition.'}, {'id': 'OG014', 'title': 'Placebo: CRYS/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fed condition.'}, {'id': 'OG015', 'title': 'Placebo: SDD/Fasted Combined for All Cohorts', 'description': 'Participants received placebo matched to PF-07293893 SDD in fasted condition.'}, {'id': 'OG016', 'title': 'Placebo: SDD/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 SDD in fed condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}, {'value': '0', 'groupId': 'OG016'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 of first dose up to maximum of 9 days post last dose (up to 34 days)', 'description': "Vital signs assessments included blood pressure, pulse rate, respiratory rate and body temperature. Clinical significance of vital signs was determined based by investigator's discretion.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}, {'value': '2', 'groupId': 'OG013'}, {'value': '2', 'groupId': 'OG014'}, {'value': '18', 'groupId': 'OG015'}, {'value': '2', 'groupId': 'OG016'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}, {'id': 'OG013', 'title': 'Placebo: CRYS/Fasted Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fasted condition.'}, {'id': 'OG014', 'title': 'Placebo: CRYS/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 CRYS in fed condition.'}, {'id': 'OG015', 'title': 'Placebo: SDD/Fasted Combined for All Cohorts', 'description': 'Participants received placebo matched to PF-07293893 SDD in fasted condition.'}, {'id': 'OG016', 'title': 'Placebo: SDD/Fed Cohort 2', 'description': 'Participants received placebo matched to PF-07293893 SDD in fed condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}, {'value': '0', 'groupId': 'OG016'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 of first dose up to maximum of 9 days post last dose (up to 34 days)', 'description': "ECG parameters included heart rate, PR interval, QTc corrected using Fridericia's formula (QTcF) and QRS complex. Clinically significant ECG findings were determined by the investigator's discretion.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.'}, {'type': 'SECONDARY', 'title': 'Maximum Plasma Concentration (Cmax) of PF-07293893', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '110.2', 'spread': '39', 'groupId': 'OG000'}, {'value': '360.1', 'spread': '19', 'groupId': 'OG001'}, {'value': '1173', 'spread': '24', 'groupId': 'OG002'}, {'value': '147.2', 'spread': '20', 'groupId': 'OG003'}, {'value': '690.6', 'spread': '23', 'groupId': 'OG004'}, {'value': '3613', 'spread': '34', 'groupId': 'OG005'}, {'value': '5632', 'spread': '28', 'groupId': 'OG006'}, {'value': '6831', 'spread': '9', 'groupId': 'OG007'}, {'value': '6203', 'spread': '22', 'groupId': 'OG008'}, {'value': '5653', 'spread': '33', 'groupId': 'OG009'}, {'value': '7894', 'spread': '15', 'groupId': 'OG010'}, {'value': '7458', 'spread': '18', 'groupId': 'OG011'}, {'value': '7398', 'spread': '22', 'groupId': 'OG012'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period', 'unitOfMeasure': 'nanogram per milliliter (ng/ mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetic (PK) parameter Set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention and had at least 1 of the PK parameters of interest calculated.'}, {'type': 'SECONDARY', 'title': 'Time for Cmax (Tmax) of PF-07293893', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.00', 'groupId': 'OG000', 'lowerLimit': '1.00', 'upperLimit': '1.03'}, {'value': '1.01', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '1.03'}, {'value': '2.03', 'groupId': 'OG002', 'lowerLimit': '1.00', 'upperLimit': '3.00'}, {'value': '2.50', 'groupId': 'OG003', 'lowerLimit': '1.00', 'upperLimit': '4.03'}, {'value': '6.00', 'groupId': 'OG004', 'lowerLimit': '4.00', 'upperLimit': '8.00'}, {'value': '2.51', 'groupId': 'OG005', 'lowerLimit': '2.00', 'upperLimit': '3.00'}, {'value': '3.51', 'groupId': 'OG006', 'lowerLimit': '2.00', 'upperLimit': '4.00'}, {'value': '2.50', 'groupId': 'OG007', 'lowerLimit': '1.00', 'upperLimit': '6.22'}, {'value': '3.01', 'groupId': 'OG008', 'lowerLimit': '1.00', 'upperLimit': '6.22'}, {'value': '5.00', 'groupId': 'OG009', 'lowerLimit': '4.00', 'upperLimit': '6.00'}, {'value': '4.00', 'groupId': 'OG010', 'lowerLimit': '3.00', 'upperLimit': '6.00'}, {'value': '4.00', 'groupId': 'OG011', 'lowerLimit': '3.00', 'upperLimit': '6.03'}, {'value': '4.01', 'groupId': 'OG012', 'lowerLimit': '3.00', 'upperLimit': '6.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period', 'unitOfMeasure': 'Hour', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter Set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention and had at least 1 of the PK parameters of interest calculated.'}, {'type': 'SECONDARY', 'title': 'Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-07293893', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '782.5', 'spread': '37', 'groupId': 'OG000'}, {'value': '2671', 'spread': '11', 'groupId': 'OG001'}, {'value': '8354', 'spread': '24', 'groupId': 'OG002'}, {'value': '2057', 'spread': '19', 'groupId': 'OG003'}, {'value': '8910', 'spread': '30', 'groupId': 'OG004'}, {'value': '29900', 'spread': '25', 'groupId': 'OG005'}, {'value': '50150', 'spread': '37', 'groupId': 'OG006'}, {'value': '89220', 'spread': '17', 'groupId': 'OG007'}, {'value': '66890', 'spread': '42', 'groupId': 'OG008'}, {'value': '80700', 'spread': '48', 'groupId': 'OG009'}, {'value': '100700', 'spread': '20', 'groupId': 'OG010'}, {'value': '103400', 'spread': '30', 'groupId': 'OG011'}, {'value': '94210', 'spread': '34', 'groupId': 'OG012'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period', 'description': 'AUClast was calculated using linear/log trapezoidal method.', 'unitOfMeasure': 'nanogram*hour per milliliter (ng*hr/ mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention and have at least 1 of the PK parameters of interest calculated.'}, {'type': 'SECONDARY', 'title': 'Area Under the Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07293893', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '799.3', 'spread': '36', 'groupId': 'OG000'}, {'value': '2700', 'spread': '11', 'groupId': 'OG001'}, {'value': '8397', 'spread': '24', 'groupId': 'OG002'}, {'value': '2219', 'spread': '20', 'groupId': 'OG003'}, {'value': '9001', 'spread': '30', 'groupId': 'OG004'}, {'value': '30010', 'spread': '25', 'groupId': 'OG005'}, {'value': '50280', 'spread': '37', 'groupId': 'OG006'}, {'value': '89780', 'spread': '17', 'groupId': 'OG007'}, {'value': '67190', 'spread': '42', 'groupId': 'OG008'}, {'value': '81070', 'spread': '49', 'groupId': 'OG009'}, {'value': '101200', 'spread': '21', 'groupId': 'OG010'}, {'value': '103900', 'spread': '30', 'groupId': 'OG011'}, {'value': '94570', 'spread': '34', 'groupId': 'OG012'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period', 'description': 'AUCinf was calculated as AUClast + (Clast\\*/kel), where Clast is the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the loglinear concentration-time curve.', 'unitOfMeasure': 'nanogram*hour per milliliter (ng*hr/ mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention and have at least 1 of the PK parameters of interest calculated.'}, {'type': 'SECONDARY', 'title': 'Terminal Half-Life (t1/2) of PF-07293893', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '12', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07293893 10 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 10 mg in fasted condition.'}, {'id': 'OG001', 'title': 'PF-07293893 30 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 30 mg in fasted condition.'}, {'id': 'OG002', 'title': 'PF-07293893 100 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD100 mg in fasted condition.'}, {'id': 'OG003', 'title': 'PF-07293893 300 mg: CRYS/Fasted Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fasted condition.'}, {'id': 'OG004', 'title': 'PF-07293893 300 mg: CRYS/Fed Cohort 2', 'description': 'Participants received PF-07293893 CRYS 300 mg in fed condition.'}, {'id': 'OG005', 'title': 'PF-07293893 300 mg: SDD/Fasted Cohort 1', 'description': 'Participants received PF-07293893 SDD 300 mg in fasted condition.'}, {'id': 'OG006', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG007', 'title': 'PF-07293893 750 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG008', 'title': 'PF-07293893 750 mg: SDD/Fasted Combined for Cohorts 2 and 3', 'description': 'Participants who received PF-07293893 SDD 750 mg in fasted condition.'}, {'id': 'OG009', 'title': 'PF-07293893 750 mg: SDD/Fed Cohort 3', 'description': 'Participants received PF-07293893 SDD 750 mg in fed condition.'}, {'id': 'OG010', 'title': 'PF-07293893 900 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 900 mg in fasted condition.'}, {'id': 'OG011', 'title': 'PF-07293893 1200 mg: SDD/Fasted Cohort 3', 'description': 'Participants received PF-07293893 SDD 1200 mg in fasted condition.'}, {'id': 'OG012', 'title': 'PF-07293893 1500 mg: SDD/Fasted Cohort 2', 'description': 'Participants received PF-07293893 SDD 1500 mg in fasted condition.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.88', 'spread': '2.8160', 'groupId': 'OG000'}, {'value': '15.32', 'spread': '1.4386', 'groupId': 'OG001'}, {'value': '13.92', 'spread': '2.0673', 'groupId': 'OG002'}, {'value': '21.50', 'spread': '6.5593', 'groupId': 'OG003'}, {'value': '13.70', 'spread': '1.2767', 'groupId': 'OG004'}, {'value': '11.34', 'spread': '2.1157', 'groupId': 'OG005'}, {'value': '10.07', 'spread': '3.0057', 'groupId': 'OG006'}, {'value': '11.00', 'spread': '1.3977', 'groupId': 'OG007'}, {'value': '10.54', 'spread': '2.2872', 'groupId': 'OG008'}, {'value': '10.90', 'spread': '1.2152', 'groupId': 'OG009'}, {'value': '10.76', 'spread': '1.3132', 'groupId': 'OG010'}, {'value': '10.44', 'spread': '2.1452', 'groupId': 'OG011'}, {'value': '9.578', 'spread': '1.1218', 'groupId': 'OG012'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period', 'description': 't1/2 was calculated as log\\^e (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.', 'unitOfMeasure': 'Hour', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Set included all participants randomly assigned to study intervention and who received at least 1 dose of study intervention and have at least 1 of the PK parameters of interest calculated.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Cohort 1: Sequence 1', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fasted): PF-07293893 10 mg; then Period 2/Day 1 (SDD, fasted): PF-07293893 30 mg; then Period 3/Day1 (SDD, fasted): PF-07293893 100 mg; then Period 4/Day1 (SDD, fasted): placebo matched to PF-07293893. SDD = spray dried dispersion form.'}, {'id': 'FG001', 'title': 'Cohort 1: Sequence 2', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fasted): PF-07293893 10 mg; then Period 2/Day 1 (SDD, fasted): PF-07293893 30 mg; then Period 3/Day1 (SDD, fasted): placebo matched to PF-07293893; then Period 4/Day1 (SDD, fasted): PF-07293893 300 mg.'}, {'id': 'FG002', 'title': 'Cohort 1: Sequence 3', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fasted): PF-07293893 10 mg; then Period 2/Day 1 (SDD, fasted): placebo matched to PF-07293893; then Period 3/Day1 (SDD, fasted): PF-07293893 100 mg; then Period 4/Day1 (SDD, fasted): PF-07293893 300 mg.'}, {'id': 'FG003', 'title': 'Cohort 1: Sequence 4', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fasted): placebo matched to PF-07293893; then Period 2/Day 1 (SDD, fasted): PF-07293893 30 mg; then Period 3/Day1 (SDD, fasted): PF-07293893 100 mg; then Period 4/Day1 (SDD, fasted): PF-07293893 300 mg.'}, {'id': 'FG004', 'title': 'Cohort 2: Sequence 1', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fasted): PF-07293893 750 mg; then Period 2/Day 1 (SDD, fasted): PF-07293893 1500 mg; then Period 3/Day1 (CRYS, fasted): PF-07293893 300 mg; then Period 4/Day1 (CRYS, fed): PF-07293893 300 mg. CRYS = crystalline form.'}, {'id': 'FG005', 'title': 'Cohort 2: Sequence 2', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fasted): PF-07293893 750 mg; then Period 2/Day 1 (SDD, fasted): PF-07293893 1500 mg; then Period 3/Day1 (CRYS, fasted): placebo matched to PF-07293893; then Period 4/Day1 (CRYS, fed): placebo matched to PF-07293893.'}, {'id': 'FG006', 'title': 'Cohort 2: Sequence 3', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fasted): PF-07293893 750 mg; then Period 2/Day 1 (SDD, fasted): placebo matched to PF-07293893; then Period 3/Day1 (CRYS, fasted):PF-07293893 300 mg; then Period 4/Day1 (CRYS, fed): PF-07293893 300 mg.'}, {'id': 'FG007', 'title': 'Cohort 2: Sequence 4', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fasted): placebo matched to PF-07293893; then Period 2/Day 1 (SDD, fasted): PF 07293893 1500 mg; then Period 3/Day1 (CRYS, fasted): PF-07293893 300 mg; then Period 4/Day1 (CRYS, fed): PF-07293893 300 mg.'}, {'id': 'FG008', 'title': 'Cohort 3: Sequence 1', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fed): PF-07293893 750 mg; then Period 2/Day 1 (SDD, fasted): PF-07293893 1200 mg; then Period 3/Day1 (SDD, fasted): PF-07293893 900 mg; then Period 4/Day1 (SDD, fasted): PF-07293893 750 mg.'}, {'id': 'FG009', 'title': 'Cohort 3: Sequence 2', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fed): PF-07293893 750 mg; then Period 2/Day 1 (SDD, fasted): PF-07293893 1200 mg; then Period 3/Day1 (SDD, fasted): placebo matched to PF-07293893; then Period 4/Day1 (SDD, fasted): PF-07293893 750 mg.'}, {'id': 'FG010', 'title': 'Cohort 3: Sequence 3', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fed): PF-07293893 750 mg; then Period 2/Day 1 (SDD, fasted): placebo matched to PF-07293893; then Period 3/Day1 (SDD, fasted): PF-07293893 900 mg; then Period 4/Day1 (SDD, fasted): PF-07293893 750 mg.'}, {'id': 'FG011', 'title': 'Cohort 3: Sequence 4', 'description': 'Participants received treatment as oral suspension in all periods. Period 1/Day1 (SDD, fed): placebo matched to PF-07293893; then Period 2/Day 1 (SDD, fasted): PF-07293893 1200 mg; then Period 3/Day1 (SDD, fasted): PF-07293893 900 mg; then Period 4/Day1 (SDD, fasted): placebo matched to PF-07293893.'}], 'periods': [{'title': 'Period 1', 'milestones': [{'type': 'STARTED', 'comment': 'Participants who entered period 1.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'No longer met eligibility criteria', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}]}, {'title': 'Period 2', 'milestones': [{'type': 'STARTED', 'comment': 'Participants who entered period 2.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}, {'type': 'Personal reason', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}]}, {'title': 'Period 3', 'milestones': [{'type': 'STARTED', 'comment': 'Participants who entered period 3.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}]}, {'title': 'Period 4', 'milestones': [{'type': 'STARTED', 'comment': 'Participants who entered period 4.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'A total of 30 participants (initially randomized participants and replacement participants) were enrolled in this study. All participants received at least 1 dose of study intervention and were assigned in the study into 3 cohorts. As planned, there were "replacement" participants in the study who were not initially randomized, but they replaced those participants who discontinued in any treatment period due to reasons other than safety; this was per investigator\'s and sponsor\'s discretion.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '30', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'Cohort 1', 'description': 'In this cohort participants were randomized to received placebo matched to PF-07293893 or PF-07293893 (10 mg, 30 mg, 100 mg or 300 mg) in sequence 1 or 2 or 3 or 4.'}, {'id': 'BG001', 'title': 'Cohort 2', 'description': 'In this cohort participants were randomized to received placebo matched to PF-07293893 or PF-07293893 (300mg \\[fast/fed\\],750 mg, 1500 mg) in sequence 1 or 2 or 3 or 4.'}, {'id': 'BG002', 'title': 'Cohort 3', 'description': 'In this cohort participants were randomized to received placebo matched to PF-07293893 or PF-07293893 (750 mg \\[fast/fed\\], 900 mg, 1200 mg) in sequence 1 or 2 or 3 or 4.'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'title': 'Age', 'categories': [{'title': '18-44 Years', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '17', 'groupId': 'BG003'}]}, {'title': '45-64 Years', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '12', 'groupId': 'BG003'}]}, {'title': '>=65 Years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '30', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '28', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}]}, {'title': 'White', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '24', 'groupId': 'BG003'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Except the replacement participants, all participants were randomized to receive all interventions in a cohort. Thus, the participants in a cohort were combined in the record.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2023-06-07', 'size': 12264641, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2025-03-21T12:33', 'hasProtocol': True}, {'date': '2024-03-21', 'size': 2966984, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2025-03-21T12:34', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 30}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-08-09', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-03', 'completionDateStruct': {'date': '2024-03-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-03-21', 'studyFirstSubmitDate': '2023-06-08', 'resultsFirstSubmitDate': '2025-03-21', 'studyFirstSubmitQcDate': '2023-06-08', 'lastUpdatePostDateStruct': {'date': '2025-04-10', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-03-21', 'studyFirstPostDateStruct': {'date': '2023-06-18', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-04-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-03-22', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'timeFrame': 'Day 1 of first dose up to maximum of 35 days post last dose (up to 60 days)', 'description': 'An Adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events with onset dates on or after the start of the study drug.'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'Day 1 of first dose up to maximum of 9 days post last dose (up to 34 days)', 'description': 'Following parameters were analyzed for laboratory abnormalities: hematology (lymphocytes \\<0.8\\*lower limit of normal \\[LLN\\], lymphocytes/leukocytes \\<0.8\\*LLN, neutrophils \\<0.8\\*LLN, neutrophils/leukocytes \\<0.8\\*LLN, eosinophils/leukocytes \\>1.2\\*upper limit of normal \\[ULN\\], monocytes \\>1.2\\*ULN, monocytes/leukocytes \\>1.2\\*ULN); clinical chemistry (aspartate aminotransferase \\>3.0\\*ULN, potassium \\>1.1\\*ULN, creatine kinase \\>2.0\\*ULN); urinalysis (urine specific gravity \\<1.003 ,\\>1.030, ketones \\>=1, urine hemoglobin \\>=1, urobilinogen \\>=1, urine bilirubin \\>=1, leukocyte esterase \\>=1). In this outcome measure, participants with any laboratory abnormalities are reported.'}, {'measure': 'Number of Participants With Clinically Significant Changes in Vital Signs', 'timeFrame': 'Day 1 of first dose up to maximum of 9 days post last dose (up to 34 days)', 'description': "Vital signs assessments included blood pressure, pulse rate, respiratory rate and body temperature. Clinical significance of vital signs was determined based by investigator's discretion."}, {'measure': 'Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings', 'timeFrame': 'Day 1 of first dose up to maximum of 9 days post last dose (up to 34 days)', 'description': "ECG parameters included heart rate, PR interval, QTc corrected using Fridericia's formula (QTcF) and QRS complex. Clinically significant ECG findings were determined by the investigator's discretion."}], 'secondaryOutcomes': [{'measure': 'Maximum Plasma Concentration (Cmax) of PF-07293893', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period'}, {'measure': 'Time for Cmax (Tmax) of PF-07293893', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period'}, {'measure': 'Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-07293893', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period', 'description': 'AUClast was calculated using linear/log trapezoidal method.'}, {'measure': 'Area Under the Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07293893', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period', 'description': 'AUCinf was calculated as AUClast + (Clast\\*/kel), where Clast is the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the loglinear concentration-time curve.'}, {'measure': 'Terminal Half-Life (t1/2) of PF-07293893', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24, 48 and 72 hours post dose of any treatment period', 'description': 't1/2 was calculated as log\\^e (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['PF-07293893', 'Single ascending dose', 'Safety', 'Tolerability', 'Pharmacokinetics'], 'conditions': ['Healthy Participants']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://pmiform.com/clinical-trial-info-request?StudyID=C5171001', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The purposes of the study are:\n\nTo learn about the safety and tolerability of study medicine (PF-07293893). Tolerability is the extent to which side effects can be tolerated. Side effects are unwanted reactions to the study medicine.\n\nTo measure the amount of PF-07293893 in blood after the medicine is taken by mouth.\n\nThe study is seeking participants who:\n\n* Are females of non-childbearing potential and males 18 to 65 years of age\n* Are in generally healthy condition\n* Have not had viral infections (HIV, HBV or HCV). HIV, human immunodeficiency virus. HBV, human hepatitis B virus. HCV, human hepatitis C virus.\n\nParticipants will receive either PF-07293893 or placebo (dummy pill) by chance. Participants will undergo up to 4 treatments periods in this study. Everyone will receive up to 4 doses of study medicine and up to 2 doses of placebo. In each period, participants will stay in study clinic for 5 days. There will be at least 2 days between each treatment period.\n\nParticipants will be involved in this study for about 14 weeks. During their stay, participants will undergo several examinations. Participants will also have their blood collected by the study doctors for several times.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "This study is seeking participants who are:\n\n* Females of non-childbearing potential and males 18 to 65 years of age, inclusive, at the time of signing the informed consent document (ICD) who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.\n\nThis study is not seeking participants who have:\n\n* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).\n* History of human immunodeficiency virus infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen, or hepatitis C antibody. Hepatitis B vaccination is allowed.\n* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to coronavirus disease 2019 (COVID-19) pandemic that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for participants \\<60 years; and ≥150/90 mm/Hg for participants ≥60 years old, following at least 5 minutes of supine rest.\n* Renal impairment as defined by an estimated glomerular filtration rate (eGFR) \\<75 mL/min/1.73m².\n* Standard 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results\n* Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:\n\nAlanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin ≥1.05 × upper limit of normal (ULN), participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN."}, 'identificationModule': {'nctId': 'NCT05907395', 'briefTitle': 'A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-07293893 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS', 'orgStudyIdInfo': {'id': 'C5171001'}, 'secondaryIdInfos': [{'id': '2023-504921-37-00', 'type': 'REGISTRY', 'domain': 'CTIS (EU)'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'PF-07293893 and Placebo (Cohort 1)', 'description': 'Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.', 'interventionNames': ['Drug: PF-07293893', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07293893 and Placebo (Cohort 2)', 'description': 'Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.', 'interventionNames': ['Drug: PF-07293893', 'Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07293893 and Placebo (Cohort 3)', 'description': 'Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.', 'interventionNames': ['Drug: PF-07293893', 'Drug: Placebo']}], 'interventions': [{'name': 'PF-07293893', 'type': 'DRUG', 'description': 'PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.', 'armGroupLabels': ['PF-07293893 and Placebo (Cohort 1)', 'PF-07293893 and Placebo (Cohort 2)', 'PF-07293893 and Placebo (Cohort 3)']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Matching placebo will be prepared as an oral suspension given in each cohort.', 'armGroupLabels': ['PF-07293893 and Placebo (Cohort 1)', 'PF-07293893 and Placebo (Cohort 2)', 'PF-07293893 and Placebo (Cohort 3)']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'B-1070', 'city': 'Brussels', 'state': 'Bruxelles-capitale, Région de', 'country': 'Belgium', 'facility': 'Pfizer Clinical Research Unit - Brussels', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}